INTERNATIONAL STUDY, MULTICENTRIC, STRATIFIED, RANDOMIZED, DOUBLE-BLIND, WITH PLACEBO OVERLOAD, IN PARALLEL GROUPS, DURING 52 WEEKS OF GASTROINTESTINAL CLINICAL SECURITY, TO DEMONSTRATE THAT COX189 (400 MG / DAY OD) REDUCES THE RISK OF DISREGARDING COMPLICATED ULCERS COMPARING WITH NSAIDS (NAPROXENO 500 MG, BID AND IBUPROPHENE 800MG.ID) IN PATIENTS WITH OSTEOARTHRITIS, COX STUDY 1189 TARGET PART II

Not Applicable

Completed

• Conditions: -M069; M069

• Registration Number: PER-022-02
• Lead Sponsor: OVARTIS BIOSCIENSES PERU S.A.,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2002-02-28
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

*Pacientes ambulatorios, mujeres u hombres que cooperen, de 50 años de edad o mas.
*Pacientes con osteoartritis primaria con sintomas desde hace por lo menos 3 meses (el diagnostico puede efectuarse en la evaluacion). En cadera, rodilla o mano, de acuerdo a los criterios ACR

Exclusion Criteria

* Patients with rheumatoid arthritis who suffer from adult juvenile chronic arthritis.
* Patient with secondary osteoarthritis with history and / or any evidence in the joint, fixed as a potential target, of the following diseases: septic arthritis, inflammatory joint disease, gout, recurrent episodes of pseudogout, disease
Paget bone, fracture, oochronosis, acromegaly, hemochromatosis, Wilson´s disease, primary osteochondromatosis, hereditary disease (eg hypermobility), mutations of the collagen gene.

Study & Design

• Study Type: Interventional
• Study Design: Not specified